Pyrroloquinoline Quinone (PQQ) for Cognitive Function

Verdict: Weak, disputed evidence; not proven to help cognition

PQQ is not proven to improve cognitive function. The only supporting human trials are small and were all funded by PQQ manufacturers, while regulators have cleared it for safety only and dementia specialists say no supplement has been shown to benefit brain health.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

This grade reflects a thin, conflicted evidence base. Four small randomized trials all point in PQQ's favor: Itoh 2016 (n=41) found a smaller Stroop interference ratio at 20 mg/day over 12 weeks (PMID 26782228); Shiojima 2022 (n=64) reported gains in memory, attention, and executive function at 21.5 mg/day (PMID 34415830); a 2023 Food & Function trial (n=62) showed improved composite and verbal memory; and a 2024 trial in mild cognitive impairment (n=34) found higher BDNF and cerebral oxygenation (PMID 38908296). But every one of these was industry-funded, none exceeded ~64 participants, and no independent or pooled meta-analysis exists.

The dispute flag is driven by the gap between these manufacturer trials and authoritative bodies. The Alzheimer's Association states plainly that 'not a single food, beverage, ingredient, vitamin or supplement has been proven to prevent, treat or cure Alzheimer's disease or to benefit cognitive function or brain health.' Mayo Clinic, Cleveland Clinic, Harvard Health, and the NIH Office of Dietary Supplements are silent on PQQ for cognition, and Examine.com has no cognitive entry for it.

Regulators add no efficacy support: the FDA's GRAS notices, EFSA, and WHO-cited assessments deem PQQ disodium salt safe up to 20 mg/day for healthy adults but authorize no health claims, and they explicitly exclude pregnant or breastfeeding women and those under 15. With 100% industry funding, small samples, and no specialty-society endorsement, the consistent-but-unverified signal earns only a weak, disputed rating rather than a positive verdict.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.50
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
39%
Conflicting evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.503
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effect of the Antioxidant Supplement Pyrroloquinoline Quinone Disodium Salt (BioPQQ) on Cognitive Functions
PMID: 26782228 2016 RCT (double-blind) n = 41
Finding: Stroop interference ratio change significantly smaller in PQQ vs placebo; Touch M improved in lower-performing PQQ subjects (baseline <70); NIRS suggested increased prefrontal blood flow; no adverse events
⚠️ Industry-funded
View on PubMed
Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
PMID: 34415830 2022 RCT (double-blind) n = 64
Finding: Significant improvements in composite memory, verbal memory, reaction time, complex attention, cognitive flexibility, executive function, and motor speed vs placebo in Japanese adults aged 40-<80; no adverse events
⚠️ Industry-funded
View on PubMed
Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults (Food & Function)
PMID: 2023 RCT (double-blind) n = 62
— See PubMed for details
View on PubMed
The impact of six-week dihydrogen-pyrroloquinoline quinone supplementation on mitochondrial biomarkers, brain metabolism, and cognition in elderly individuals with mild cognitive impairment: a rand…
PMID: 38908296 2024 RCT (double-blind) n = 34
Finding: BDNF significantly elevated in PQQ arm at 6 wk (p=0.01) vs placebo (p=0.27); cognitive orientation interaction effect p=0.03 favoring supplement; cerebral oxygenation rose 48.4% to 52.8% (p=0.005); NAA increased at 7/13 brain locations (p<=0.05) in MCI elderly
⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FDA has no questions at this time regarding [the notifier's] conclusion that pyrroloquinoline quinone (PQQ) disodium salt is GRAS under the intended conditions of use. source↗
L4b EU EFSA
Neutral
The Panel concludes that the NF, pyrroloquinoline quinone disodium salt (BioPQQ™), is safe under the intended conditions of use as specified by the applicant. source↗
L4c UK NHS
Not addressed
Food Supplements as defined in Directive 2002/46/EC intended for the adult population, excluding pregnant and lactating women. ... This food supplement should be consumed by adults only excluding pregnant and lactating women. source↗
L4e WHO
Supportive
Pyrroloquinoline quinone disodium salt produced by fermentation using Hyphomicrobium denitrificans CK-275 is safe under the intended conditions of use. The applicant intends to market PQQ for use in food supplements for healthy adults, except pregnant and lactating women, at a maximum proposed level of consumption of 20 mg/day (corresponding to 0.29 mg/kg bw per day for a 70-kg person). source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cognitive-function-INT-pyrroloquinoline-quinone-001 繁體中文版 →